Multispecific (HHLL)2 Molecules for Multi-Antigen Targeting
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing bispecific molecules face challenges in efficiently targeting multiple antigens, stability, and large-scale production, particularly in addressing tumor escape mechanisms and low antigen expression, with existing formats struggling to balance therapeutic efficacy, pharmacokinetic properties, and production efficiency.
Innovation Solution
Development of novel (HHLL)2 format molecules with four immunoglobulin variable domains and flexible peptide linkers, optionally including an Fc region, to enhance stability and expression, allowing efficient production and improved binding to immune effector and target cells.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If traditional bispecific molecule formats are used, then therapeutic efficacy is achieved, but stability and production efficiency deteriorate
Solution Approach 1:
The molecule is divided into four distinct binding domains (VH1-VL1, VH2-VL2, VH3-VL3, VH4-VL4) connected by flexible linkers, allowing each domain to function independently while maintaining overall structural stability. This segmentation enables the molecule to target multiple antigens simultaneously while preserving therapeutic efficacy and improving stability.
Solution Approach 2:
The invention combines multiple immunoglobulin variable domains (VH and VL regions) with flexible peptide linkers to create a composite molecular structure. This composite format integrates the binding specificity of scFv domains with the stability of a multi-domain architecture, achieving both therapeutic efficacy and improved molecular stability.
2Adaptability or versatility
If complex multi-specific molecules are designed to target multiple antigens, then tumor escape mechanisms are addressed, but manufacturing complexity increases
Solution Approach 1:
The four binding domains are segmented and connected in a linear sequence with flexible linkers, creating a modular structure that can target multiple antigens. This segmentation allows the molecule to address tumor escape mechanisms by simultaneously engaging multiple antigens while maintaining a relatively simple linear architecture that facilitates manufacturing.
Solution Approach 2:
The molecule is designed with four different binding domains that can recognize and bind to different antigens simultaneously. This multi-functionality enables the molecule to target multiple antigens on tumor cells and immune cells, providing versatility in addressing various tumor escape mechanisms while maintaining a unified molecular structure.
3Reliability
If larger multi-domain molecules are constructed to improve binding affinity, then target cell binding is enhanced, but production efficiency decreases
Solution Approach 1:
The invention optimizes the parameters of the molecular structure by using flexible peptide linkers of specific lengths between domains and selecting appropriate VH-VL pairings. These parameter changes enhance target cell binding affinity through improved spatial arrangement and avidity effects while maintaining a size and structure that are amenable to efficient large-scale production in mammalian cell systems.
Data Source
AI summary
New formats of multispecific molecules are described, as well as their methods of making. Additionally, uses in therapeutic indications are also described.